ClinicalTrials.gg
CompletedNCT07178353FABRICUpdated Nov 12, 2026

Human Skeletal Muscle Response to 5 Days of Bedrest in Young Adults

An interventional study of Bedrest in Muscular Atrophy, Insulin Resistance and Muscle Protein Synthesis, sponsored by Queen's University. Completed at 1 site in Canada. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Queen's University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 12, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Muscular Atrophy with a site in Canada — 1 open to participants now, 2 under way, 1 of them phase 3. Muscular Atrophy · Canada.

Enrollment
23rd of 27
14 · median 26
Started
2025
the only one that year
No phase
19 of 29
none open now
Registered
29th of 29
by date
Lead sponsor
2 of 29
Queen's University

Among the 29 studies in Muscular Atrophy with a site in Canada, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2025, is one of 19 with no phase, and was the 29th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

1 of the 29 studies in Muscular Atrophy with a site in Canada is open now. Recruiting first, the newest first:

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Muscular Atrophy with a site in Canada, or all of them as a file.
02

Study summary

The goal of this intervention trial is to characterize skeletal muscle atrophy in healthy, young adults during short term bedrest. The main questions it aims to answer are:

How much do skeletal muscle volume, strength, and fatigue resistance decline during bedrest? How much does whole-body insulin sensitivity change during bedrest? How do mitochondrial function and protein synthesis change during bedrest?

Participants will undergo the following tests before and after a free-living control period and before and after a 5 day period of strict horizontal bedrest:

  • Magnetic resonance imaging of the thigh muscles
  • Strength testing of the thigh muscles
  • Insulin sensitivity testing in response to a mixed meal
  • Exogenous glucose oxidation in response to a mixed meal
  • Muscle biopsies from the thigh muscles
  • Blood samples
Read the detailed description

Skeletal muscle plays a critical role in physical function and metabolic health, with its maintenance driven by the balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB). During periods of disuse, such as illness or injury, MPS declines while MPB remains relatively unchanged, leading to muscle loss and atrophy. Short-term disuse, such as bedrest, is commonly experienced through hospitalization, and can result in rapid declines in muscle mass and strength, typically affecting the lower limbs to a greater extent. At the molecular level, bed rest significantly reduces MPS, with durations as little as 3 days showing drastic impairment in skeletal muscle turnover. Additionally, short-term periods of disuse have shown to blunt mitochondrial respiration, affecting the ability for skeletal muscle to produce energy for proper funcitoning and metabolic processes. Diminished skeletal muscle metabolic function directly impacts whole-body metabolic health. Periods of bedrest between 5 and 7 days have shown to decrease whole-body glucose tolerance, increase insulin resistance, and decrease insulin-stimulated leg glucose uptake. All together, these contribute to decreased skeletal muscle mass and strength, and diminished metabolic function, contributing to a decline in overall physical function, health, and well-being. Current studies on short-term bed rest (ex. 5 days) in young adults are limited, and existing research has focused on simulated microgravity models rather than horizontal bed rest, which better represents clinical scenarios. Additionally, no study to our knowledge has explored how the molecular mechanisms that drive MPS change over the course of a 5-day bedrest period. This highlights a need to explore if there are differences in the attrition of synthesis rates of the different protein pools in skeletal muscle (ex. myofibrillar, sarcoplasmic, and mitochondrial).

The purpose of the present study is to investigate changes in leg muscle mass, strength, and whole-body insulin sensitivity over five days of bed rest, as well as examine the time-course changes in molecular mechanisms underlying skeletal muscle turnover. The investigators hypothesize that, compared to the control period, quadriceps muscle size (volume and cross-sectional area), strength/power/fatigue resistance, and whole-body insulin sensitivity will decrease following bedrest. The investigators hypothesize that these outcomes will be linked to decreases in mitochondrial respiratory function and impaired fractional synthetic rates of muscle proteins.

In this repeated-measures design, participants will undergo a five day baseline control period followed by five days of bed rest to compare changes from bedrest to their own free-living control period.

Findings from this study will help inform future research on the impact of short-term, clinically-relevant, bedrest in young adults and aid in the development of targeted interventions to mitigate declines in muscle mass from occurring from acute bouts of muscle disuse.

03

Conditions studied

  • Muscular Atrophy
  • Insulin Resistance
  • Muscle Protein Synthesis

Keywords

  • magnetic resonance imaging
  • muscle protein syntheis
  • muscle disuse atrophy
  • bedrest
  • skeletal muscle
  • insulin sensitivity
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 18-30 years
  • between 18.5-28 kg/m2
  • Weight stable (within ±2kg for 6 months)
  • Generally healthy as assessed by medical and physical activity questionnaires
  • recreationally active

Exclusion criteria

Exclusion Criteria:

  • a \< 18.5 and > 28 kg/m2
  • the use of insulin to control blood glucose levels
  • a history of any cardiovascular, respiratory, metabolic diseases, neuromuscular or bone-wasting diseases
  • the use of any medication that may affect muscle protein turnover (e.g. androgen or anabolic hormone therapy, chemotherapy)
  • a (family) history of thrombosis, or coagulation disorders, or antiplatelet therapy and the use of anticoagulant medications
  • the presence of any unremoved, or partially removed metals underneath the skin
  • a history of head or eye injury involving metal fragments
  • have some type of implanted electrical device (such as a cardiac pacemaker or neurostimulator)
  • have implanted metal objects as a result of surgery, such as artificial joints, aneurysm clips, metal staples
  • are, or may be, pregnant
  • are wearing metal braces on their teeth.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Experimental: Bedrest

    19 day study period, consisting of baseline testing, 5 days of free-living (habitual daily activities) immediately followed by 5 days of strict bedrest. Diet controlled and physical activity monitored for entire study period.

    Other: Bedrest

Interventions

  • OtherBedrest

    5 days of strict bedrest. Participants are allowed to sit up in bed, but will perform any bathing or bathroom activities in a wheelchair.

    Also known as: Horizontal Bedrest

06

What researchers measure

Primary outcomes

  1. Quadriceps muscle volume

    Quadriceps muscle volume will be assessed by magnetic resonance imaging.

    Time frame: Day 0, and 5

Secondary outcomes

  1. Muscle strength

    Knee extensor peak torque will be assessed using dynamometry

    Time frame: Day -14, -9, and 5

  2. Knee extensor power

    Peak isotonic power determined at 30% maximal isometric voluntary contraction torque using a dynamometer

    Time frame: Day -14, -9, and 5

  3. Muscle fatiguability

    Knee extensor fatiguability will be determined by the decrease in isotonic power across 40 contractions at 30% MVC using dynamometry.

    Time frame: Day -14, -9, and 5

  4. Muscle cross-sectional area

    Change in quadriceps muscle cross sectional area measured by magnetic resonance imaging scan.

    Time frame: Day 0 and 5

  5. Muscle protein synthesis

    Muscle protein synthesis measured as fractional synthesis rate of the myofibrillar, sarcoplasmic, and mitochondrial protein pools within skeletal muscle. These 3 pools will be assessed using combined protocol of skeletal muscle biopsy, stable isotope tracing, cavity ring down spectroscopy with liquid isotope analysis, and gas-chromatography pyrolysis isotope-ratio mass spectrometry.

    Time frame: Day -5 to 0, day 0 to 1, day 0 to 3, day 0 to 5, day 1 to 3, day 1 to 5, and day 3 to 5.

  6. 2-hour plasma glucose incremental area under the curve

    Determination of the total rise in plasma glucose during a mixed meal tolerance test, to be assessed by an enzyme-linked immunosorbent assay.

    Time frame: Aggregate 2-hour window on day -5, 0, and 5

  7. 2- hour plasma insulin incremental area under the curve

    Determination of the total rise in plasma insulin during a mixed meal tolerance test, to be assessed by an enzyme-linked immunosorbent assay.

    Time frame: Aggregate 2-hours on day -5, 0, and 5

  8. Postprandial glucose oxidation

    Measurement of 13C excretion in breath samples using isotope ratio mass spectrometry.

    Time frame: Aggregate 3 hours during the mixed meal tolerance test on day -5, 0, and 5

  9. Matsuda Index

    Insulin sensitivity measured via the Matsuda Index during a mixed meal tolerance test. Matsuda index values \<4.0 indicate insulin resistance, with higher values representing insulin sensitivity.

    Time frame: 2-hours on day -5, 0, and 5

  10. Mitochondrial Respiratory Function

    Mitochondrial respiration will be assessed using an Oroboros Oxygraph 2000.

    Time frame: Day -5, 1, 3, and 5

  11. Expression of Translational Factors Related to Skeletal Muscle Protein Synthesis

    Activation of translational factors involved in skeletal muscle protein synthesis assessed by western blotting.

    Time frame: Day 0, 1, 3, and 5

  12. Plasma glucose concentration

    Plasma glucose concentration measured during a mixed meal tolerance test.

    Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5

  13. Serum insulin concentration

    Serum insulin concentration measured during a mixed meal tolerance test

    Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5

  14. Peak glucose concentration

    Peak glucose concentration measured during a mixed meal tolerance test

    Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5

  15. Peak insulin concentration

    Peak insulin concentration measured during a mixed meal tolerance test.

    Time frame: 2-hour mixed meal tolerance test on day -5, 0, and 5

  16. Transmission Electron Microscopy Analysis

    Imaging of subsarcolemmal and intermyofibrillar mitochondria to assess change in mitochondrial content from bedrest.

    Time frame: Day 0, 1, 3, and 5

  17. Supine to Stand Test

    Orthostatic blood pressure assessment pre and post bedrest, and following recovery after bedrest

    Time frame: Day 0, 5

  18. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    Insulin resistance assessed using fasting insulin and glucose levels. Values \<1.0 indicate insulin sensitivity, \>1.9 and \< 2.9 indicates early insulin resistance, and values \>2.9 indicate significant insulin resistance

    Time frame: Day -5, 0, and 5

07

Study locations

1 site
  • Queen's Univeristy
    Kingston, Ontario K7L 3N6, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Jun 2026, 9 months.

Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 9 months is below that.

Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Jun 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 17, 2025
StartActual
Sep 1, 2025
Primary completionActual
Jun 9, 2026
CompletionActual
Jun 9, 2026was Jun 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Study completion
Jun 2027→Jun 9, 2026 (actual)
Nov 12, 2026
Enrollment
12 (estimated)→14 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Study completion Jun 2027→Jun 9, 2026 (now actual)
    Enrollment 12 (estimated)→14 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07178353
Lead sponsor
Queen's University
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Dr. Chris McGlory, PhD (Associate Professor, Kingston Health Sciences Centre) — Principal investigator
First posted
Sep 17, 2025
Start date
Sep 1, 2025
Primary completion
Jun 9, 2026
Completion
Jun 9, 2026
Last update
Nov 12, 2026

Study contacts

Chris McGlory, PhD.
principal investigator · Queen's University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion